Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | AXL | P30530 | 4/20 | 0.38 |
| ▸ | MERTK | Q12866 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.37 |
| ▸ | PTGES | O14684 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407713 | 1.00 | CHRM2 (0.47) | CHRM2KCNA5CHRM1HRH3KDM4E | |
| SCHEMBL13697341 | 0.88 | JAK2 (0.49) | CHRM2KDM4EALDH1A1MAPT | |
| SCHEMBL1134427 | 0.79 | STS (0.50) | KDM4EALDH1A1MAPT | |
| SCHEMBL3405533 | 0.79 | STS (0.50) | KDM4EALDH1A1MAPT | |
| SCHEMBL8002644 | 0.79 | STS (0.50) | KDM4EALDH1A1MAPT | |
| SCHEMBL8001931 | 0.78 | MERTK (0.40) | CHRM2KCNA5AXLMERTKADRB2 | |
| SCHEMBL13697321 | 0.77 | STS (0.50) | KDM4EALDH1A1MAPT | |
| SCHEMBL3408089 | 0.74 | OPRK1 (0.36) | — | |
| SCHEMBL1929028 | 0.74 | SMN1; SMN2 (0.54) | CHRM2CHRM1HRH3 | |
| SCHEMBL8002677 | 0.72 | KDM1A (0.53) | KCNA5AXLMERTKADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885KCNA5 204/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.